MX2020012979A - Métodos para aumentar la exposición al plasma de sepiapterina. - Google Patents

Métodos para aumentar la exposición al plasma de sepiapterina.

Info

Publication number
MX2020012979A
MX2020012979A MX2020012979A MX2020012979A MX2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A MX 2020012979 A MX2020012979 A MX 2020012979A
Authority
MX
Mexico
Prior art keywords
methods
increasing
sepiapterin
plasma exposure
sepiapterin plasma
Prior art date
Application number
MX2020012979A
Other languages
English (en)
Inventor
Neil Smith
Jonathan Reis
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2020012979A publication Critical patent/MX2020012979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención presenta composiciones farmacéuticas que incluyen sepiapterina, o una sal farmacéuticamente aceptable de la misma, y métodos para el tratamiento de trastornos relacionados con el BH4. En algunas modalidades, estas composiciones y métodos dan por resultado un incremento en la exposición a plasma, LCR, y/o cerebro de sepiapterina.
MX2020012979A 2018-05-30 2019-05-30 Métodos para aumentar la exposición al plasma de sepiapterina. MX2020012979A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US201962822376P 2019-03-22 2019-03-22
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Publications (1)

Publication Number Publication Date
MX2020012979A true MX2020012979A (es) 2021-04-29

Family

ID=68699037

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012979A MX2020012979A (es) 2018-05-30 2019-05-30 Métodos para aumentar la exposición al plasma de sepiapterina.

Country Status (8)

Country Link
US (2) US11617752B2 (es)
EP (1) EP3801536A4 (es)
JP (1) JP2021525729A (es)
CN (1) CN112703002A (es)
AU (1) AU2019277382A1 (es)
CA (1) CA3102106A1 (es)
MX (1) MX2020012979A (es)
WO (1) WO2019232130A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
EP3675863A4 (en) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. PHARMACEUTICAL COMPOSITION CONSISTING OF SEPIAPTERIN AND ITS USES
AU2021209935A1 (en) * 2020-01-24 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating Parkinson's disease with sepiapterin
AU2022221345A1 (en) * 2021-02-09 2023-09-07 Ptc Therapeutics Mp, Inc. Methods for treating glioblastomas with sepiapterin
US20240122931A1 (en) * 2021-02-09 2024-04-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
CA2543315A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
WO2005049614A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
CN1894251B (zh) 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
AU2005313940A1 (en) 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
JP5042843B2 (ja) 2005-04-28 2012-10-03 白鳥製薬株式会社 ヒドラゾン類の製造法
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
JP2010523708A (ja) 2007-04-11 2010-07-15 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
WO2011132435A1 (ja) * 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
ES2681345T3 (es) 2012-05-07 2018-09-12 Shiratori Pharmaceutical Co., Ltd. Método para producir sepiapterina y tetrahidrolactoilpterina
EP3213062B1 (en) 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
EP3548487A4 (en) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
EP3675863A4 (en) 2017-09-01 2021-01-27 PTC Therapeutics MP, Inc. PHARMACEUTICAL COMPOSITION CONSISTING OF SEPIAPTERIN AND ITS USES
KR102642601B1 (ko) * 2017-11-23 2024-03-05 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시 장치 및 전자 기기
KR20210038848A (ko) 2018-05-30 2021-04-08 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 제약상 허용되는 염
JP2021525746A (ja) 2018-05-30 2021-09-27 ピーティーシー セラピューティクス エムピー，インコーポレイテッド テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
AU2020324435A1 (en) 2019-08-05 2022-02-24 Ptc Therapeutics Mp, Inc. Use of sepiapterin and metabolites thereof to treat radiation exposure
EP4034122A1 (en) 2019-09-25 2022-08-03 PTC Therapeutics MP, Inc. Methods for treating hyperphenylalaninemia

Also Published As

Publication number Publication date
AU2019277382A1 (en) 2021-01-21
CA3102106A1 (en) 2019-12-05
EP3801536A4 (en) 2022-03-23
EP3801536A1 (en) 2021-04-14
US20230381181A1 (en) 2023-11-30
JP2021525729A (ja) 2021-09-27
WO2019232130A1 (en) 2019-12-05
US20210220363A1 (en) 2021-07-22
CN112703002A (zh) 2021-04-23
US11617752B2 (en) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MY186271A (en) Ophthalmic compositions and methods of use therefor
IL287280A (en) Compounds and methods for the treatment of ocular disorders
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
IL287264A (en) Compounds and methods for the treatment of ocular disorders
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
JOP20200041A1 (ar) تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.